Business
Change of Auditor
Change of Auditor.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n24 November 2023\n \nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nChange of Auditor\n \nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that RPG Crouch Chapman LLP has been appointed as its new independent auditor with immediate effect.\n \nThe Board has approved the appointment of RPG Crouch Chapman LLP as the Company's auditor for the financial year ending 31 December 2023. The re-appointment of RPG Crouch Chapman LLP for the financial year ending 31 December 2024 will be subject to approval by shareholders at the next Annual General Meeting of the Company to be held in 2024.\n \nIn accordance with Section 519 of the Companies Act 2006, the Company's previous auditor, BDO LLP, has confirmed that there are no circumstances connected with their resignation which they considered should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.\n \nENDS\nEnquiries:\n\n\n\n\nRoquefort Therapeutics plc\n\n\n\n\nStephen West (Chairman) / Ajan Reginald (CEO)\n\n\n+44 (0)20 3918 8633\n \n\n\n\n\nHybridan LLP (Joint Broker)\nClaire Louise Noyce\n \nOptiva Securities Limited (Joint Broker)\n\n\n \n+44 (0)203 764 2341\n\n\n\n\nChristian Dennis\n \nBuchanan (Public Relations)\nBen Romney / Jamie Hooper / George Beale\n \n\n\n+44 (0)20 3411 1881\n \n \n+44 (0)20 7466 5000\n \n\n\n\n\n \nLEI: 254900P4SISIWOR9RH34\n \nAbout Roquefort Therapeutics\nRoquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.\n \nSince listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.\n \nRoquefort Therapeutics' portfolio consists of...